Form 4: AbbVie Executive Jeffrey R. Stewart Sells Shares and Exercises Options
SEC Form 4 Filing
EVP and Chief Commercial Officer of AbbVie, Jeffrey R. Stewart, reports the sale of AbbVie shares and exercise of stock options on March 18, 2024.
Summary
- On March 18, 2024, Jeffrey R. Stewart, EVP and Chief Commercial Officer of AbbVie Inc., executed transactions involving AbbVie's common stock.
- Stewart exercised options to acquire 26,110 shares at a price of $61.36 per share.
- He also sold a total of 58,949 shares in multiple transactions at weighted average prices of $178.85, $179.03, and $178.69.
- Following these transactions, Stewart directly owns 60,941 shares and indirectly owns 1,338 shares through a spouse's trust.
- He also holds options for 0 shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. The sentiment is neither positive nor negative as it simply reports required information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of AbbVie's top executives. Investors often monitor these filings for insights into management's perspective on the company's stock and future prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies like AbbVie, similar to filings made by executives at comparable pharmaceutical companies such as Johnson & Johnson (JNJ) and Pfizer (PFE).
- The reporting requirements are governed by Section 16(a) of the Securities Exchange Act of 1934, ensuring consistent disclosure across the industry.
- The level of detail provided, including weighted average prices for multiple transactions, aligns with regulatory expectations for transparency.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, as insider selling can sometimes be interpreted negatively, although this appears to be a routine transaction.
- The exercise of stock options could slightly dilute existing shareholders' equity.
Key Dates
| Date | Description |
|---|---|
| 02/16/2018 | Date the options were exercisable |
| 02/15/2027 | Expiration date of the options |
| 03/18/2024 | Date of the stock option exercise and share sales |
| 03/20/2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.